POET TECHNOLOGIES - THE WAFER-SCALE CPO BET

Apr 25, 2026

∙ Paid

SEQH CAPITAL RESEARCH - TEAR SHEET
POET TECHNOLOGIES - THE WAFER-SCALE CPO BET

WHAT THIS REPORT ANSWERS

The report explains why POET Technologies (NASDAQ: POET / TSX: PTK) is a credible but more balanced photonics equity setup, with a wafer-scale Optical Interposer platform spanning pluggable transceivers and CPO external light sources, but with valuation and dilution already discounting a lot of future execution.
SEQH initiates POET at MARKETWEIGHT, not OVERWEIGHT, because the core architecture and customer set are real, but the stock already prices in a successful 2026 to 2027 ramp that has not yet shown up in recurring revenue.

Core thesis

POET’s Optical Interposer integrates InP and GaAs active devices onto a 200mm silicon waveguide substrate with passive alignment, which SEQH argues is a real architectural answer to the scaling bottlenecks in conventional silicon photonics and InP-only designs.
The same platform supports 100G, 400G, 800G, 1.6T, and eventually 3.2T transceivers, plus ELS modules for CPO, giving POET multiple entry points into the AI datacenter optical stack rather than a single product bet.
SEQH’s view is that the platform is credible enough to matter, but the investment debate is now less about technical validity and more about whether POET can convert disclosed relationships into material revenue fast enough.

The 2026 to 2028 ramp is anchored by four production-oriented engagements: FIT, Luxshare-ICT, Marvell via Celestial AI, and Lessengers plus LITEON, with management targeting shipment of more than 30,000 optical engines in 2026.
FIT is framed as the highest-impact catalyst because PO conversion would reset revenue assumptions, while Luxshare is expected to be the largest contributor to the 2026 engine target based on its long-standing OEM role and broad customer channel.
Marvell is the strategic wildcard and the highest-margin bridge into CPO and ELS, with POET’s CFO confirming on April 21, 2026 that the Celestial relationship continued under Marvell and that shipments begin in Q2 2026.
Lessengers and LITEON add a second 1.6T path into higher-volume datacenter optics, which reduces dependence on any single transceiver OEM even if FIT remains the main near-term swing factor.

The Sivers Semiconductors partnership is a key enabler of POET’s ELS roadmap because POET does not have in-house InP manufacturing and needs a high-volume DFB array supplier for Starlight ELS.
Under the partnership, Sivers supplies DFB laser arrays and POET integrates them into ELS modules on the Optical Interposer, with prototypes targeted in H1 2026 and production readiness targeted by end-2026.
SEQH views the partnership as strategically rational and additive, but not existential for either side, since POET has its own Blazar internal ELS path and Sivers also has other ELS relationships.

FY25 was the first year of real commercial recognition, with revenue rising to $1.07M from $41K in FY24, Q4 2025 revenue at $341,202, and year-end cash plus short-term investments at $313.4M, or about $430M pro forma after the January 2026 raise.
That capital rebuild gives POET more than 12 quarters of runway at FY25 burn rates, but it came at a steep cost: shares outstanding rose from 89.8M to about 152.7M, with another 43.2M warrants and options still overhanging the stock.
SEQH’s base revenue bridge moves from $1.07M in FY25 to $16M in FY26, $55M in FY27, and $120M in FY28, showing how much of the valuation depends on forward conversion rather than present earnings power.

At $15.10 on April 24, 2026, POET had a market cap of about $2.3B, up 138% YTD, which leaves traditional EV/sales effectively meaningless on current revenue and pushes the debate into private photonics peer comps and scenario analysis instead.
SEQH compares POET against names such as Ayar Labs, Lightmatter, and Celestial AI, arguing POET is not obviously expensive against private platform comps, but does deserve a discount for public-market liquidity, disclosed dilution, and first-volume execution risk.
The 12-month scenario framework lands at $8.50 bear, $15.00 base, $24.00 bull, and a probability-weighted price target of $15.63, which is why SEQH lands on MARKETWEIGHT rather than a more aggressive rating.

The biggest risks are not technological but financial and behavioral: dilution, valuation dislocation, and timing risk around FIT purchase orders, Marvell ELS shipments, and broader CPO adoption.
SEQH highlights customer concentration as a major issue, with FIT, Luxshare, and Marvell representing roughly 80% of the disclosed pipeline, and warns that any slip in one or more of those programs could quickly compress the equity.
The report also flags the Wolfpack PFIC overhang, future financing risk, and any delay in Sivers DFB integration as secondary issues that matter most because the stock has already run far ahead of the FY25 financial base.

Upgrade to access the full POET Technologies deep-dive, including:

The full Optical Interposer architecture breakdown across transceivers, ELS, and CPOwith manufacturing network detail across SilTerra, Xiamen, Globetronics, and NationGate.
A detailed customer and partnership map covering FIT, Luxshare, Marvell, Lessengers, LITEON, Sivers, Mitsubishi, QCi, and Adtran, along with scenario revenue ranges by vector through FY28.
Full valuation work, dilution analysis, catalyst calendar, and the POET-Sivers relationship section that frames where the company sits in the broader AI photonics stack.

FULL POET EQUITY REPORT PLUS ACCESS TO ALL FUTURE RESEARCH BELOW: